iRegene Therapeutics' NouvNeu001 Receives FDA Fast Track Designation, Marking Global First for iPSC-Derived Off-the-Shelf Cell Therapy in Parkinson’s Disease
iRegene Therapeutics
Cell Therapy Product Developer
August 18, 2025, Easycapital's long-term partner — iRegene announced its core productNouvNeu001 Granted FDA Fast Track DesignationThis important milestone marks the company's globally innovative position in the field of Parkinson's disease cell therapy gaining international authoritative recognition, and also brings new treatment hope to millions of patients worldwide.
As a benchmark enterprise in China's cell therapy field, iRegene has successfully developed a new generation of cell therapy products with precise targeting, leveraging its internationally leading induced pluripotent stem cell (iPSC) technology platform. The recent granting of FDA Fast Track designation will not only accelerate the product’s approval process in the United States but also highlights the breakthrough progress of China's innovative pharmaceutical companies in the global drug development landscape.
Since 2023, Easy Capital has continuously supported the growth of iRegene, serving as the exclusive financial advisor for multiple rounds of financing and assisting the company in completing hundreds of millions of RMB in cumulative funding.iRegene has established an innovative pipeline covering major fields such as neurodegenerative diseases and ophthalmic diseases, and has taken the lead in achieving an international layout with dual IND filings in China and the United States. This breakthrough progress by the FDA is a significant testament to the company's technical strength and commercialization process.
The following is the news sharing for this milestone event:
On August 15, 2025, NouvNeu001 Injection, independently developed by iRegene (Chengdu) Co., Ltd., receivedFDA Granted Fast Track Designation (FTD) and Approved Expanded Indications, Marking the World's First FTD Qualification for a Universal iPSC-Derived Parkinson's Cell Therapy Product.This global breakthrough not only marks iRegene's leading position in the field of cell therapy worldwide but also reflects the firm commitment and efficient execution of the iRegene team to bring innovative solutions to Parkinson's patients.
iRegene Therapeutics' iPSC-derived project NouvNeu001, in addition to receiving FDA Special Exemption in March 2024, has further obtained support from the FDA's FTD Accelerated Pathway. This significant milestone marksNouvNeu001 officially enters the international fast track, marking the US FDA's high recognition of iRegene's NouvNeu001 clinical data.iRegene's NouvNeu001 Demonstrates Statistically Significant Safety Data Over 15 Months in Phase I Clinical Trials. More importantly, the Phase I clinical data not only shows significantly superior results compared to similar cell therapy products but also surpasses existing clinical treatment methods with statistically significant outcomes. The MDS-UPDRS Part III scores reflect a faster improvement time window and more substantial improvement magnitude.
Following the granting of FTD status, the FDA will engage in more frequent interactions with iRegene. The FDA will provide targeted one-on-one guidance to iRegene on aspects such as clinical trial design and data requirements. Additionally, iRegene has also obtained the qualification for rolling communication with the FDA without time restrictions. More importantly, the granting of this FTD also allows iRegene’s NouvNeu001 to expand its application scope for use in other compassionate use cases. More notably, the FTD can be implemented in parallel with Breakthrough Therapy Designation (BTD), Priority Review, and Accelerated Approval, speeding up the market entry process of iRegene's NouvNeu001 and bringing this drug of significant clinical importance to market as soon as possible.
// Dr. Cai Meng, CMO of iRegene, stated:
This milestone event indicates that the clinical value of NouvNeu001 has gained recognition from global regulatory authorities. Moreover, due to its breakthrough effectiveness in treating Parkinson's disease, the FDA has not only provided customized support for the regulation and market approval of NouvNeu001 but has also agreed to expand its use to other compassionate use scenarios, significantly enhancing the clinical application value and commercial potential of NouvNeu001.
Globally, iRegene Therapeutics' iPSC-derived universal cell therapy project NouvNeu001 (chemically induced dopaminergic neural progenitor cells) has received multiple designations from the FDA. First, in March 2024, it obtained special exemption from the FDA, and in June 2024, its IND was approved to initiate an international multicenter Phase I clinical trial in the United States and other countries. On August 15, 2025, iRegene further received Fast Track Designation (FTD) from the FDA, making it the world's first iPSC-derived universal Parkinson’s cell therapy product to be granted FDA Fast Track Designation (FTD). Prior to this, Aspen Neuroscience’s ANPD001 (autologous iPSC-derived dopaminergic neural progenitors) received FTD designation in October 2023, and BlueRock Therapeutics’ OpCT-001 (iPSC-derived photoreceptor cells) received FTD designation in February 2025. Bemdaneprocel (BRT-DA01), developed by BlueRock Therapeutics as a cell therapy product derived from embryonic stem cells, received RMAT (Regenerative Medicine Advanced Therapy) designation in August 2023. This breakthrough further solidifies iRegene's leading position in the global industry.
// Milestone Timeline for iRegene Therapeutics' NouvNeu001 Project:
On August 3, 2023, NouvNeu001 received approval from China's NMPA to conduct Phase I/II combined clinical trials in China targeting moderate to severe Parkinson's disease.
In December 2023, NouvNeu001 officially launched its Phase I clinical trial at the National Center for Geriatrics and Gerontology, Beijing Hospital, Ministry of Health;
In March 2024, the U.S. FDA granted NouvNeu001 special exemption status, recognizing iRegene's breakthrough innovation platform and comprehensive quality system, and exempting NouvNeu001 from related U.S. Pharmacopeia requirements.
In June 2024, the U.S. FDA approved its IND to initiate an international multi-center Phase I clinical trial in the United States and other countries;
In November 2024, NouvNeu001 completed the enrollment for Phase I clinical trial in China;
In April 2025, NouvNeu001 officially launched the Phase II clinical trial in China;
From April to June 2025, iRegene launched the overseas multi-center Phase I clinical trial of NouvNeu001 in multiple countries;
In July 2025, the first group of patients in the Phase II clinical trial of NouvNeu001 completed dosing;
On August 15, 2025, further granted FDA Fast Track Designation (FTD).
Fast Track Designation (FTD) is an expedited development and review pathway by the U.S. Food and Drug Administration (FDA), designed to accelerate the approval and market entry of new drugs that treat serious or life-threatening diseases and address unmet medical needs. Key benefits include more frequent regulatory interactions and rolling review. In 1997, FTD was formally established as part of the FDA Modernization Act (FDAMA). FTD stands alongside the FDA’s three other expedited programs—Breakthrough Therapy Designation (BTD), Accelerated Approval (AA), and Priority Review (PR)—as one of the four acceleration tools for "serious conditions—unmet needs." In 2012, the FTD strategy was further revised and strengthened under the FDASIA.
